MedPath

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Interventions
Drug: bimatoprost 0.01% ophthalmic solution
First Posted Date
2012-05-02
Last Posted Date
2014-06-13
Lead Sponsor
Allergan
Target Recruit Count
419
Registration Number
NCT01589510

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

Phase 1
Completed
Conditions
Rosacea
Erythema
Interventions
Drug: AGN-199201 Formulation A
Drug: AGN-199201 Formulation B
Drug: AGN-199201 Formulation C
Drug: AGN-199201 Vehicle
First Posted Date
2012-04-17
Last Posted Date
2019-11-18
Lead Sponsor
Allergan
Target Recruit Count
64
Registration Number
NCT01579084

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Phase 3
Completed
Conditions
Muscle Spasticity
Interventions
Biological: botulinum toxin Type A
Drug: Normal Saline
First Posted Date
2012-04-11
Last Posted Date
2016-09-28
Lead Sponsor
Allergan
Target Recruit Count
468
Registration Number
NCT01575054

A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)

Completed
Conditions
Macular Edema
Retinal Vein Occlusion
Interventions
Drug: dexamethasone 700 ug intravitreal implant
First Posted Date
2012-04-05
Last Posted Date
2019-04-19
Lead Sponsor
Allergan
Target Recruit Count
573
Registration Number
NCT01571557

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed
Conditions
Open-Angle Glaucoma
Ocular Hypertension
Interventions
Drug: Bimatoprost 0.01% ophthalmic solution
First Posted Date
2012-04-02
Last Posted Date
2013-09-20
Lead Sponsor
Allergan
Target Recruit Count
933
Registration Number
NCT01568008

Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

Completed
Conditions
Macular Edema
Retinal Vein Occlusion
Interventions
Other: No Intervention
First Posted Date
2012-04-02
Last Posted Date
2015-02-10
Lead Sponsor
Allergan
Target Recruit Count
100
Registration Number
NCT01568021

Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

Completed
Conditions
Retinal Vein Occlusion
Macular Oedema
Interventions
Drug: dexamethasone intravitreal implant 0.7 mg
First Posted Date
2012-03-29
Last Posted Date
2013-05-27
Lead Sponsor
Allergan
Target Recruit Count
26
Registration Number
NCT01566526

Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

First Posted Date
2012-03-08
Last Posted Date
2014-08-15
Lead Sponsor
Allergan
Target Recruit Count
135
Registration Number
NCT01547598

Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)

Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Interventions
Other: No Treatment
First Posted Date
2012-02-28
Last Posted Date
2013-09-19
Lead Sponsor
Allergan
Target Recruit Count
102
Registration Number
NCT01540370

A Long-Term Safety Study of OZURDEX® in Clinical Practice

Completed
Conditions
Retinal Vein Occlusion
Macular Edema
Uveitis, Posterior
Interventions
Drug: dexamethasone 700 μg intravitreal implant
First Posted Date
2012-02-27
Last Posted Date
2016-04-20
Lead Sponsor
Allergan
Target Recruit Count
875
Registration Number
NCT01539577
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy